258 related articles for article (PubMed ID: 32625092)
1. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.
De Mattia E; Roncato R; Palazzari E; Toffoli G; Cecchin E
Front Pharmacol; 2020; 11():897. PubMed ID: 32625092
[TBL] [Abstract][Full Text] [Related]
2. Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of Treatment Response in Locally Advanced Rectal Cancer Patients.
Troncarelli Flores BC; Souza E Silva V; Ali Abdallah E; Mello CAL; Gobo Silva ML; Gomes Mendes G; Camila Braun A; Aguiar Junior S; Thomé Domingos Chinen L
Cells; 2019 Jun; 8(7):. PubMed ID: 31247977
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
4. Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response.
Pazdirek F; Minarik M; Benesova L; Halkova T; Belsanova B; Macek M; Stepanek L; Hoch J
Front Oncol; 2020; 10():1028. PubMed ID: 32793464
[No Abstract] [Full Text] [Related]
5. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
Clancy C; Burke JP; Coffey JC
Surg Oncol; 2013 Jun; 22(2):105-11. PubMed ID: 23473635
[TBL] [Abstract][Full Text] [Related]
7. Identification of proteomic markers for prediction of the response to 5-Fluorouracil based neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Wang J; Liu J; Wang J; Wang S; Li F; Li R; Liu P; Li M; Wang C
Cancer Cell Int; 2022 Mar; 22(1):117. PubMed ID: 35292026
[TBL] [Abstract][Full Text] [Related]
8. Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker.
Kim S; Yeo MK; Kim JS; Kim JY; Kim KH
J Cancer; 2022; 13(1):162-173. PubMed ID: 34976180
[No Abstract] [Full Text] [Related]
9. The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis.
Zhong X; Zhou Y; Cui W; Su X; Guo Z; Hidasa I; Li Q; Wang Z; Song Y
Front Pharmacol; 2020; 11():706. PubMed ID: 32499700
[TBL] [Abstract][Full Text] [Related]
10. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
[TBL] [Abstract][Full Text] [Related]
11. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
13. Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer.
Dayde D; Gunther J; Hirayama Y; Weksberg DC; Boutin A; Parhy G; Aguilar-Bonavides C; Wang H; Katayama H; Abe Y; Do KA; Hara K; Kinoshita T; Komori K; Shimizu Y; Tajika M; Niwa Y; Wang YA; DePinho R; Hanash S; Krishnan S; Taguchi A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298853
[TBL] [Abstract][Full Text] [Related]
14. Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy: A Systematic Review and Meta-Analysis.
De Mattia E; Polesel J; Mezzalira S; Palazzari E; Pollesel S; Toffoli G; Cecchin E
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900260
[TBL] [Abstract][Full Text] [Related]
15. The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.
Abdul-Jalil KI; Sheehan KM; Toomey S; Schmid J; Prehn J; O'Grady A; Cummins R; O'Neill B; McNamara DA; Deasy J; Breathnach O; Grogan L; Rogers A; Doherty G; Winter D; Ryan J; El-Masry S; Gibbons D; Sheahan K; Gillen P; Kay EW; Hennessy BT
Ann Surg Oncol; 2014 Aug; 21(8):2642-9. PubMed ID: 24700299
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
17. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer.
Jia H; Shen X; Guan Y; Xu M; Tu J; Mo M; Xie L; Yuan J; Zhang Z; Cai S; Zhu J; Zhu Z
Radiother Oncol; 2018 Sep; 128(3):548-556. PubMed ID: 30041962
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
19. The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Dou X; Wang R; Meng X; Yan H; Jiang S; Zhu K; Xu X; Chen D; Song X; Mu D
Cancer Biomark; 2015; 15(2):181-8. PubMed ID: 25519018
[TBL] [Abstract][Full Text] [Related]
20. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
